abiraterone has been researched along with Carcinoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gschwend, J; Miller, K; Ohlmann, CH | 1 |
| Rexer, H | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Balk, SP; Bubley, GJ; Cai, C; Chen, S; Marck, B; Matsumoto, AM; Mostaghel, EA; Nelson, PS; Ng, P; Simon, NI; Wang, H | 1 |
| Arlt, W; Attard, G; Auchus, RJ; Cassidy, AM; de Bono, JS; Dowsett, M; Folkerd, E; Hughes, BA; Oommen, NB; Reid, AH; Thompson, E | 1 |
1 review(s) available for abiraterone and Carcinoma
| Article | Year |
|---|---|
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
1 trial(s) available for abiraterone and Carcinoma
| Article | Year |
|---|---|
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Pharmacological; Carcinoma; Chemotherapy, Adjuvant; Disease Progression; Enzyme Inhibitors; Glucocorticoids; Humans; Male; Models, Biological; Orchiectomy; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2012 |
3 other study(ies) available for abiraterone and Carcinoma
| Article | Year |
|---|---|
[Androgen deprivation plus abiraterone/prednisone in metastatic hormone-sensitive prostate cancer : Joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Humans; Male; Medical Oncology; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms; Treatment Outcome; Urology | 2017 |
[Non-interventional study of metastatic castration-resistant prostate cancer. Prospective, non-interventional trial on the influence of adherence to abiraterone treatment in patients with metastatic, castrate-resistant prostate cancer (IMPACT) - trial AP
Topics: Administration, Oral; Androstenes; Antineoplastic Agents; Carcinoma; Germany; Humans; Male; Medication Adherence; Prevalence; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Treatment Outcome | 2015 |
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Topics: Androstenedione; Androstenes; Androstenols; Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cell Line, Tumor; Dehydroepiandrosterone; Female; Humans; Indomethacin; Male; Mice; Orchiectomy; Pregnenolone; Progesterone; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Up-Regulation | 2011 |